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Resolvins are generated from omega-3 fatty acids during inﬂammatory responses in the
lung.These natural mediators interact with speciﬁc receptors to decrease lung inﬂamma-
tionandpromoteitsresolutioninhealthytissues.Thereareseverallungdiseasesofchronic
inﬂammation that fail toresolve, most notable asthma.This common disorder has a lifetime
prevalence of nearly 10% and is characterized, in part, by chronic, non-resolving inﬂamma-
tion of the airway. Pro-resolving mediators are generated during asthma; however, their
biosynthesis is decreased in severe and uncontrolled asthma, suggesting that the chronic,
adaptive inﬂammation in asthmatic airways may result from a resolution defect.This article
focuses on recent insights into the cellular and molecular mechanisms for resolvins that
limit adaptive immune responses in healthy airways.
Keywords: resolution, resolvins, inﬂammation, lung, asthma
INTRODUCTION
The recent identiﬁcation of specialized mediators that promote
tissue resolution from acute inﬂammation and injury has opened
anewwindowfordiscoveryof cellularandmolecularmechanisms
governingchronicinﬂammationandadaptiveimmunity.Chronic
“unresolved”inﬂammation is a pathologic response that is associ-
ated with several common human diseases for which there is no
cure. Asthma is an exemplary illness with chronic inﬂammation
thathasalifetimeprevalenceof nearly1in10inWesterncountries
(Fanta,2009).Thechronicinﬂammationinasthmaconsistsofair-
way inﬁltration of eosinophils and T-lymphocytes with increased
levels of pro-phlogistic cytokines and lipid mediators (Busse and
Lemanske, 2001). Of interest, many patients with uncontrolled
Abbreviations: ALX/FPR2, lipoxin A4 receptor/formyl peptide receptor
2; AT-RvD1, aspirin-triggered-resolvin D1 (7S,8R,17R-trihydroxy-docosa-
4Z,9E,11E,13Z,15E,19Z-hexaenoic acid); AT-RvD2, aspirin-triggered-resolvin
D2 (7S,16R,17R-trihydroxy-docosa-4Z,8E,10Z,12E,14E,19Z-hexaenoic acid);
AT-RvD3, aspirin-triggered-resolvin D3 (4S,11R,17R-trihydroxy-docosa-
5,7E,9E,13Z,15E,19Z-hexaenoic acid); AT-RvD4, aspirin-triggered-resolvin
D4 (4S,5R,17R-trihydroxy-docosa-6E,8E,10Z,13Z,15E,19Z-hexaenoic acid);
BALF, bronchoalveolar lavage ﬂuid; BLT1, LTB4 receptor; CMKLR1,
chemokine receptor-like 1; DHA, docosahexaenoic acid; EPA, eicosapentaenoic
acid; LC-UV-MS/MS, liquid chromatography-ultraviolet spectrometry-
tandem mass spectrometry; LOX, lipoxygenase; LTB4, leukotriene B4
(5S,12R-dihydroxy-eicosa-6Z,8E,10E,14Z-tetraenoic acid); LXA4, lipoxin
A4 (5S,6R,15S-trihydroxy-eicosa-7E,9E,11Z,13E-tetraenoic acid); PD1, pro-
tectin D1 (10R,17S-dihydroxy-docosa-4Z,7Z,11E,13E,15Z,19Z-hexaenoic
acid); RvD1, resolvin D1 (7S,8R,17S-trihydroxy-4Z,9E,11E,13Z,15E,19Z-
docosahexaenoic acid); RvD2, resolvin D2 (7S,16R,17S-trihydroxy-docosa-
4Z,8E,10Z,12E,14E,19Z-hexaenoic acid); RvD3, resolvin D3 (4S,11,17S-
trihydroxy-5E,7E,9E,13Z,15E,19Z-docosahexaenoic acid); RvD4, resolvin D4
(4S,5,17S-trihydroxy-6E,8E,10Z,13Z,15E,19Z-docosahexaenoic acid); RvE1,
resolvin E1 (5S,12R,18R-trihydroxy-6Z,8E,10E,14Z,16E-eicosapentaenoic acid);
RvE2,resolvin E2 (5S,18R-dihydroxy-8Z,11Z,14Z,16E-eicosapentaenoic acid;SAA,
serum amyloid A; TGF-b, transforming growth factor-beta.
lung inﬂammation, including clinically severe asthma, display a
defect in the generation of specialized pro-resolving mediators
(Levyetal.,2005,2007;Planagumaetal.,2008;Table1),consistent
with a failure to establish sufﬁcient protective counter-regulatory
pathways in the asthmatic lung.
Catabasis is a healthy host tissue response to noxious stim-
uli. The literal deﬁnition of catabasis refers to a military retreat
and the term has been adopted for use to describe the resolution
process of returning an inﬂamed or injured tissue to homeostasis
after the“battle”of inﬂammation. Catabasis requires well orches-
tratedcellularresponsesinwhichsolublemediatorsappeartoplay
criticalroles(Serhan,2007).Forresolution(Majno,1996),restitu-
tion of endothelial and epithelial cell barrier integrity is necessary
to prevent continued edema formation. Additional granulocyte
recruitment is blocked and those granulocytes that have inﬁl-
trated the tissue undergo programmed cell death. The apoptotic
cells are then cleared, principally by macrophages. The phago-
cytes also clear tissue microbes and debris, and structural cells
re-establish organ function. One family of mediators for these
pro-resolving cellular actions is the resolvins, which are enzymat-
ically derived from the omega-3 fatty acids eicosapentaenoic acid
(i.e., E-series resolvins) and docosahexaenoic acid (i.e., D-series
resolvins; Serhan et al., 2000, 2002). Together with the lipoxins,
protectins, and maresins, the resolvins comprise a new genus of
endogenous, specialized pro-resolving mediators (Serhan, 2007).
These mediators serve as agonists at select receptors to trans-
duce their cell type speciﬁc pro-resolving actions (Serhan, 2007).
Defects in resolvin signaling pathways can be resolution “toxic”
in model systems, leading to conversion of acute inﬂammatory
responsestomorechronicpathologicinﬂammation(Schwabetal.,
2007), supporting a potential link for defective resolvin signaling
to chronic inﬂammatory diseases. Of interest, there appears to be
population heterogeneity in resolution mechanisms. Randomly
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Table 1 | Uncontrolled lung inﬂammation –A defect in specialized pro-resolving mediators.
Pro-resolving mediator Disease Finding Reference
Lipoxin A4 Aspirin-exacerbated
respiratory disease
Aspirin-tolerant asthmatics generate more
lipoxins than aspirin-intolerant asthmatics
Sanak et al. (2000), Celik et al. (2007),
Yamaguchi et al. (2011)
Severe asthma Diminished lipoxin biosynthesis in severe
asthma
Levy et al. (2005), Vachier et al. (2005),
Celik et al. (2007), Planaguma et al.
(2008), Bhavsar et al. (2010), Wu et al.
(2010), Fritscher et al. (2012)
Bronchoconstriction in
asthma
Protects against bronchoprovocation by either
LTC4 or exercise
Tahan et al. (2008), Christie et al. (1992)
Asthma exacerbation Decreased lipoxin levels in exhaled breath
during exacerbation
Hasan et al. (2012)
Cystic ﬁbrosis Decreased generation and actions in cystic
ﬁbrosis
Karp et al. (2004),Yang et al. (2012),
Chiron et al. (2008), Mattoscio et al. (2010)
Scleroderma lung disease Decreased lipoxin levels in BALFs Kowal-Bielecka et al. (2005)
Resolvin E1 Cystic ﬁbrosis Decreased resolvin E1 levels in cystic ﬁbrosis
with a relationship to lung function
Yang et al. (2012)
Protectin D1 Asthma exacerbation Decreased Protectin D1 in uncontrolled asthma Levy et al. (2007)
selected healthy individuals display signiﬁcant differences in the
pace of resolution for acute exudative inﬂammation with segre-
gation of these apparently healthy subjects into discrete cohorts
of rapid and delayed resolvers (Morris et al., 2010) that may
be partially explained by genetic variability, which has recently
been linked to inﬂammatory disease (Simiele et al., 2011). In
health, the conversion of acute to chronic airway inﬂammation
is prevented by endogenous pro-resolving mechanisms for tissue
catabasis.
Intrinsically linked to innate immune responses, the develop-
mentof adaptiveimmunityisessentialtohostdefense,butunreg-
ulated adaptive inﬂammation can also lead to disease, including
autoimmune disorders, transplant rejection, and allergy. As part
of a series of review articles exploring the research theme of“Res-
olution of inﬂammation: leukocytes and molecular pathways as
potential therapeutic targets,”this article will focus on the regula-
tionof adaptiveinﬂammatoryresponsesbyresolvins,inparticular
sharedanddistinctcounter-regulatorymechanismsforresolvinE1
and resolvin D1 in allergic inﬂammation.
RESOLVINS AND THEIR RECEPTORS IN THE LUNG
Eicosapentaenoic acid is an essential fatty acid that can be enzy-
matically converted to E-series resolvins, including resolvin E1,
resolvin E2, and resolvin E3, during inﬂammation in mammals
and ﬁsh (Serhan et al., 2000; Isobe et al., 2012). These media-
tors display stereoselective and cell type speciﬁc actions. Resolvin
E1 (5S,12R,18R-trihydroxy-6Z,8E,10E,14Z,16E-eicosapentaenoic
acid) can transduce its biological actions by interacting with spe-
ciﬁcG-proteincoupledreceptors,namelychemokine-likereceptor
1 (CMKLR1) and leukotriene B4 receptor 1 (BLT1; Arita et al.,
2005a, 2007). RvE1 serves as an agonist for CMKLR1, which is
expressed in macrophages, dendritic cells (DCs), natural killer
(NK) cells, and other T cells, and RvE1 serves as a receptor
antagonistatBLT1forleukotrieneB4.BLT1isexpressedongranu-
locytes,Tcells,andmacrophages.ResolvinE1andresolvinE2(5S,
18R-dihydroxy-6E,8Z,11Z,14Z,16E-eicosapentaenoic acid) are
generated via the actions of 5-lipoxygenase (ALOX5) from
a common precursor 18-hydroxyeicosapentaenoic acid (18-
HEPE) with two parallel stereospeciﬁc pathways (Arita et al.,
2005a; Tjonahen et al., 2006; Oh et al., 2012). Resolvin
E3 [17,18(R/S)-dihydroxy-5Z,8Z,11Z,13E,15E-eicosapentaenoic
acid] is distinct from RvE1 and RvE2 because it is generated
via the actions of 12/15-lipoxygenase (ALOX12/15; Isobe et al.,
2012). Since ALOX5 and ALOX12/15 are generally compart-
mentalized into distinct leukocyte classes, neutrophils (ALOX5)
appear to play signiﬁcant roles in RvE1 and RvE2 genera-
tion, while eosinophils (ALOX12/15) are signiﬁcant in RvE3
biosynthesis.
Docosahexaenoic acid is another essential omega-3 fatty
acid that can be enzymatically converted to resolvins. In a
lipoxygenase-dependent manner, DHA is transformed to D-
series resolvins, including resolvin D1–D6, during inﬂamma-
tion (Serhan, 2007). These mediators also display stereoselec-
tive and cell type speciﬁc actions. Resolvin D1 (7S,8R,17S-
trihydroxy-4Z,9E,11E,13Z,15E,19Z-docosahexaenoic acid) trans-
duces its biological actions by interacting with speciﬁc G-protein
coupled receptors, including the lipoxin A4 receptor ALX/FPR2
and, in humans, GPR32 (Sun et al., 2007; Krishnamoorthy
et al., 2010, 2012). RvD1 serves as an agonist for both of these
receptors. ALX/FPR2 is broadly expressed in many cells types,
including most leukocytes as well as structural cells, such as air-
way epithelial cells (Chiang et al., 2006). GPR32 is expressed
on phagocytes (Krishnamoorthy et al., 2010). There are also
aspirin-triggered 17R D-series resolvins (AT-RvD1–4) that are
generated in human and murine tissues, including lung, and
AT-RvD1 can also interact with ALX/FPR2 and GPR32 recep-
tors (Krishnamoorthy et al., 2012). Of note, in an aspirin-
independent manner, cytochrome P450 enzymes, which are
abundant in the lung, can also convert DHA to 17R-hydroxy-
DHA that can serve as a precursor for 17R-RvD1 (i.e., AT-
RvD1), so the presence of aspirin is not required for AT-RvD1
generation.
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Relatively little information is currently available on most of
these recently identiﬁed E-series and D-series resolvins regarding
their actions during lung inﬂammation; however,recent evidence
has identiﬁed important roles for resolvin E1 and resolvin D1 and
their cellular targets in promoting the resolution of lung inﬂam-
mation (Aoki et al., 2008; Haworth et al., 2008, 2011; Seki et al.,
2010; Bilal et al.,2011;Wang et al.,2011; Eickmeier et al.,2012; El
Kebir et al., 2012; Rogerio et al., 2012), including allergic airway
responses (Aoki et al.,2008; Haworth et al.,2008,2011; Bilal et al.,
2011; Rogerio et al., 2012).
EXPRESSION OF CMKLR1 – CELL TYPE, LUNG TISSUE,
ASTHMA
CMKLR1 is highly expressed in immature plasmacytoid DCs and
at lower levels in myeloid DCs, macrophages, and NK cells (Arita
et al., 2005a; Parolini et al., 2007). The CMKLR1 signaling path-
way is structurally and functionally conserved between human
and mouse. In a model of zymosan induced peritonitis,CMKLR1
deﬁcientmice,exhibitincreasedinﬂammation,indicatingthatthis
receptorisimportantforcounter-regulatorysignaling(Cashetal.,
2008). Both RvE1 and chemerin can interact with CMKLR1 and
displaypotentanti-inﬂammatorypropertiesinLPS-inducedacute
lung inﬂammation in mice, reducing neutrophil inﬁltration and
inﬂammatory cytokine release in a CMKLR1-dependent manner
(Luangsay et al., 2009).
The expression of CMKLR1 in plasmacytoid DCs suggests
an important role in anti-viral immunity. When wild-type and
CMKLR1 knock-out mice are infected by pneumonia virus of
mice, the CMKLR1 deﬁcient mice display higher mortality and
morbidity,alteration of lung function,delayed viral clearance and
increased neutrophilic inﬁltration. The CMKLR1 deﬁcient mice
have a lower recruitment of plasmacytoid DCs and a reduction
in type I interferon production. Recruitment of plasmacytoid
DCs via CMKLR1 contributes to adaptive immune responses and
viral clearance, but also enhances the inﬂammatory response.
Anti-inﬂammatory pathways involving CMKLR1 expressed by
non-leukocytic cells in the lung also contribute to the increased
morbidity/mortality in CMKLR1 deﬁcient mice (Bondue et al.,
2011).
Of interest, CMKLR1 signaling in acute lung inﬂammation
appears context dependent. In a separate model of acute lung
inﬂammation, cigarette smoke-induced lung inﬂammation was
attenuated in CMKLR1 deﬁcient mice with decreased levels of
inﬂammatory chemokines and inﬂammatory cells. In addition,
the inﬁltration of leukocytes persists for 14days after cessation of
smokeexposureinthismodelinwild-typemice,buttheCMKLR1
deﬁcient mice have a marked decrease in lung T cells at this time
point (Demoor et al.,2011). Together,these ﬁndings indicate that
theRvE1receptorCMKLR1isexpressedinthelungbybothleuko-
cytesandstructuralcellsandCMLKR1signalingplayspivotalroles
in the regulation of innate and adaptive immune cell activation in
the lung.
The recruitment of CMKLR1-expressing leukocytes to the
lung is regulated during inﬂammatory responses. Following acute
LPS-induced lung inﬂammation, NK cells expressing CMKLR1
are recruited to the airways in a CCRL2-dependent manner.
Engagement of CCRL2 on endothelial cells initiates adhesion
of CMKLR1-expressing lymphoid cells through an a(4)b(1)
integrin/VCAM-1-dependent mechanism. CCRL2 expression by
endothelial cells is regulated by cell activation, so CMKLR1-
dependent lymphocyte adhesion to endothelial cells can be tar-
geted to sites of inﬂammation,including inﬂamed lung (Monnier
et al., 2012).
EXPRESSION OF ALX/FPR2 – CELL TYPE, LUNG TISSUE,
ASTHMA
ALX/FPR2 is expressed in several types of leukocytes (Chiang
etal.,2006),includingneutrophils(Fioreetal.,1992,1994),mono-
cytes (Maddox and Serhan, 1996), eosinophils (Levy et al., 2002),
myeloid progenitors (Stenke et al., 1991), NK cells (Ramstedt
et al., 1987; Haworth et al., 2011), and activated T cells (Ariel
et al., 2003), as well as resident cells such as macrophages (God-
son et al., 2000), synovial ﬁbroblasts (Sodin-Semrl et al., 2000),
and intestinal epithelial cells (Gronert et al., 1998). ALX/FPR2 is
expressed in murine and human lung (Planaguma et al., 2008;
Rogerio et al., 2012), airway epithelial cells (Bonnans et al., 2003,
2006), and alveolar macrophages (Rogerio et al., 2012). As early
as 2h after acute lung injury or inﬂammation,ALX/FPR2 expres-
sion increases in mucosal epithelial cells (Bonnans et al., 2006).
Counter-regulatory signaling via ALX/FPR2 has been demon-
stratedinvivousingALX/FPR2deﬁcientmice(Duftonetal.,2010)
and transgenic mice that express human ALX/FPR2 directed by a
component of the myeloid CD11b promoter (Devchand et al.,
2003). ALX/FPR2 deﬁcient mice have more marked inﬂamma-
toryresponseswithincreasedleukocyteadherenceandemigration
into inﬂamed tissue after ischemia-reperfusion injury and after
carrageenan-induced paw edema. In addition, ALX/FPR2 knock-
out mice display increased sensitivity to arthrogenic serum and
fail to resolve from this chronic inﬂammatory arthritis (Dufton
et al., 2010). Also of note, human ALX/FPR2-transgenic mice
have decreased inﬂammatory responses and are protected from
the development of allergic airway inﬂammation with markedly
decreased eosinophil activation and tissue accumulation (Levy
etal.,2002).Inasthma,ALX/FPR2receptorexpressionisregulated
in a cell type speciﬁc manner with decreases in peripheral blood
neutrophilandeosinophilexpressioninthischronicinﬂammatory
condition (Planaguma et al., 2008).
Recently, in subjects with chronic obstructive pulmonary dis-
ease, serum amyloid A (SAA) was identiﬁed as a biomarker for
acute exacerbations (Bozinovski et al., 2008). SAA can also inter-
act with ALX/FPR2 receptors, and unlike RvD1 or LXA4, the
SAA-ALX/FPR2 interactions are pro-inﬂammatory (Bozinovski
et al., 2012). Because plasma levels of SAA are at least two-log
orders higher than LXA4 during acute exacerbations (Bozinovski
et al., 2012), the pro-inﬂammatory SAA-ALX/FPR2 signaling can
overwhelm the pro-resolving mediator protective signaling at this
receptor.ThebalanceofALX/FPR2ligandsduringasthmaandthe
inﬂuence of corticosteroids is a subject of on-going investigation.
ALLERGIC AIRWAY RESPONSES – AN EXPERIMENTAL
MODEL OF ADAPTIVE IMMUNITY AND ASTHMA
Animal models have not been developed that fully resemble
human asthma, but they are quite useful for investigation of
adaptive immunity and asthma traits. To model allergic airway
www.frontiersin.org December 2012 | Volume 3 | Article 390 | 3 
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inﬂammation, animals are ﬁrst sensitized to an allergen and then
challenged by respiratory tract exposure to the same allergen
(Kips et al., 2003; Corry and Irvin, 2006; Pichavant et al., 2007;
Zosky and Sly, 2007). Roles for representative family members
of D-series resolvins and E-series resolvins have been determined
using a model in which chicken ovalbumin (OVA) serves as an
allergen for in-bred mice. The animals are sensitized by intraperi-
toneal injection of OVA combined with the adjuvant aluminum
hydroxide to initiate a strong Th2 phenotype (Aoki et al., 2008;
Haworth et al., 2008, 2011; Bilal et al., 2011; Rogerio et al., 2012).
In sensitized mice, OVA aerosol challenge on four consecutive
days leads to adaptive inﬂammation consisting of predominantly
eosinophils and T-lymphocytes, in particular in medium to small
airwaysandalveoli(Levy,2010).Thereisalsoperivascularinﬂam-
mation. Antigen-induced responses also increase airway mucus
metaplasia and hyper-responsiveness (Levy, 2010). To determine
the extent of the airway hyper-responsiveness, methacholine is
administered via inhalation while the mice are intubated and
sedatedonaventilatorcircuit.Adoseresponsecurveisconstructed
for methacholine-initiated changes in lung resistance.
In most instances, the airway inﬂammation of asthma in
humans does not resolve completely; however, in healthy airways,
inhalation of potential allergens or provocative stimuli leads to an
acute inﬂammatory response that is self-limited. Several classes
of natural anti-inﬂammatory mediators,including resolvins,have
been identiﬁed in inﬂamed airways (Bilal et al., 2011; Eickmeier
etal.,2012).Becausetheclinicalpresentationof asthmaisafterthe
disease has already developed, more recent research has focused
on the natural factors that promote resolution of allergic air-
way responses and identiﬁcation of potential disease mechanisms
that counter these endogenous, protective signals to perpetuate
inﬂammation and potentially maladaptive airway responses. In
the murine model of allergic airway responses described above,
the cessation of OVA aerosol challenge leads to self-limited lung
inﬂammation with resolution of the adaptive immune responses
within 1–2weeks (Haworth et al., 2008). Investigation of the res-
olution phase of allergic airway responses has uncovered several
pro-resolvingmolecularandcellularmechanismsforadaptiveair-
way inﬂammation (Levy et al., 2007; Haworth et al., 2008, 2011;
Rogerio et al., 2012). NK cells were recently assigned important
roles for clearance of antigen-speciﬁc T cells. During the nat-
uralresolutionphaseof allergicairwayinﬂammation,eosinophils,
and T cells decrease markedly concomitant with an increase in
the numbers of NK cells in the lung and associated mediasti-
nal lymph nodes (Haworth et al., 2011). These resolution NK
cells also acquire cell surface markers, including NKG2D, consis-
tent with NK cell activation (Haworth et al., 2011). The timely
resolution of allergic airway inﬂammation is prolonged when
NK cells are depleted, blocked from interacting with target cells,
or inhibited from migrating to the lung, leading to a persis-
tence of airway eosinophils and antigen-speciﬁc CD4 (Haworth
et al., 2011) T cells (Haworth et al., 2011). Lung macrophages
also serve important pro-resolving roles in the clearance of aller-
gic airway inﬂammation. After the respiratory tract is exposed
to allergen, lung macrophages display a signiﬁcant capacity for
clearance of airway antigen that was introduced during aerosol
challenge (Rogerio et al., 2012). These recent ﬁndings identify
important pro-resolving roles for innate lung tissue lympho-
cytes and macrophages in the regulation of adaptive immune
responses.
ACTIONS OF RvD1 AND RvE1 IN ALLERGIC AIRWAY
INFLAMMATION
LC-MS/MS-based lipido-metabolomic analyses of inﬂamed
murine lung reveals picogram quantities of RvD1 and RvE1 that
can be increased several fold with increased substrate availabil-
ity (Bilal et al., 2011; Eickmeier et al., 2012). In asthma, airway
mucosal epithelial cells have depleted stores of docosahexaenoic
acid (Freedman et al.,2004) and lower levels of 17-hydroxy-DHA
and protectin D1 in exhaled breath condensates compared with
healthy control subjects (Levy et al.,2007). Recently,the potential
beneﬁcial actions of resolvins in experimental models of airway
mucosal inﬂammation have been reported.
Lung expression of the RvD1 receptor ALX/FPR2 is induced
in vivo in allergic airway inﬂammation (Levy et al., 2002). When
RvD1 is given to OVA-sensitized mice just prior to OVA aerosol
challenge, the development of allergic airway responses is sig-
niﬁcantly decreased (Rogerio et al., 2012). In particular, RvD1
markedly decreases eosinophils and levels of IL-4,IL-5,and IL-13
in bronchoalveolar lavage ﬂuids (BALFs), consistent with a dom-
inant effect of the mediator on the development of Th2 adaptive
inﬂammation.Regulationof thesecytokinesbyRvD1isassociated
with a signiﬁcant increase in lung IkBa,suggesting decreased acti-
vation of NF-kB. Airway mucus metaplasia is also decreased by
RvD1 with a more modest effect on airway hyper-responsiveness
to methacholine. BALF levels of the counter-regulatory mediators
IL-10 and LXA4 are not increased by RvD1 administration, indi-
cating non-redundant anti-inﬂammatory signaling circuits for
these mediators.
PotentregulationbyRvD1andAT-RvD1of theallergen-driven
accumulation of eosinophils was linked to signiﬁcant decrements
in BALF IL-5, eotaxin, and LTB4 (Rogerio et al., 2012). In many
asthmatics, a Th2 cytokine gene expression signature is induced
(Woodruff et al., 2007), including IL-5, which is an important
cytokine for the recruitment and activation of eosinophils, espe-
cially in conjunction with eotaxins (Busse and Lemanske, 2001).
IL-5,eotaxin,NF-kB activation (Yang et al.,1998),and LTB4 (Ter-
awaki et al., 2005) can all increase airway eosinophilia. In murine
allergic airway inﬂammation,RvD1 and AT-RvD1 decreased each
of these mediators of eosinophil activation and accumulation.
Eosinophils may also play important roles in airway remod-
eling and can generate the pro-ﬁbrotic growth factor TGF-b1
(Wongetal.,1991).TheRvD1andAT-RvD1mediateddecreasein
eosinophils and TGF-b levels (Rogerio et al., 2012) suggest addi-
tional beneﬁcial actions for these mediators in preventing chronic
airwayremodeling.Furtherstudyinmodelsof chronicinﬂamma-
tion is needed to address this potential tissue protective role for
these D-series resolvins.
When administered after acute airway inﬂammation is estab-
lished, RvD1 signiﬁcantly and rapidly decreases the allergic lung
inﬂammation within 1h (Rogerio et al., 2012). Because RvD1
is subject to rapid inactivation in the lung, it is impact is tran-
sient (Rogerio et al., 2012), so when RvD1 is given daily for three
consecutive days, there is only a modest decrease in the BALF
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eosinophil resolution interval over the subsequent week (Rogerio
etal.,2012).Ofnote,anequivalentdoseandadministrationofAT-
RvD1(s0.005mg/kg)providessigniﬁcantlygreaterpro-resolving
actions than RvD1, including a marked decrease in the BALF
eosinophil resolution interval by more than 50% – an approxi-
mate doubling of the pace of resolution! Both of these D-series
resolvins are agonists at ALX/FPR2 receptors albeit with differ-
ent binding kinetics (Perretti et al., 2002; Krishnamoorthy et al.,
2010, 2012; Norling et al., 2012). In addition, the metabolism of
these epimers is distinct (Sun et al.,2007). In the presence of lung
macrophages, AT-RvD1 has a decreased rate of metabolic inacti-
vation relative to RvD1 (Rogerio et al.,2012). RvD1 andAT-RvD1
are diastereomers, differing only in stereochemistry at carbon 17
(reviewed in Serhan et al., 2008). This change in stereochem-
istry forAT-RvD1 provides a signiﬁcant increase in the mediator’s
half-life in vivo, secondary to resistance to metabolic inactivation
by eicosanoid oxidoreductases (Sun et al., 2007; Krishnamoorthy
et al., 2012).
AT-RvD1 displays potent pro-resolving actions on molecular
and cellular inﬂammatory responses. During resolution of aller-
gic airway responses,BALF levels of IL-17,eotaxin,TARC,TGF-b,
and LTB4 are signiﬁcantly decreased by AT-RvD1 administration
(Rogerioetal.,2012).Fortissuecatabasisafterantigenchallenge,it
is essential to clear the allergen from the lung. Lung macrophages
play critical roles in this catabatic process (Thornton et al.,
2012).AT-RvD1 increases the macrophage phagocytosis index for
OVA in vitro and in vivo (Rogerio et al., 2012). By promoting
more rapid allergen clearance by lung macrophages, AT-RvD1
accelerates the pace of resolution of allergic airway responses,
namely adaptive airway inﬂammation, mucus metaplasia, and
hyper-responsiveness to methacholine.
Resolvin E1 is also a potent anti-inﬂammatory and pro-
resolving mediator for allergic airway responses. Similar to RvD1,
RvE1 can prevent the development allergic airway responses in
this murine model of asthma (Levy et al., 2002, 2007; Haworth
et al.,2008).When RvE1 is administered intravenously,it potently
inhibits the induction of allergic airway inﬂammation (Aoki
et al., 2008; Haworth et al., 2008) and when given during the
resolution phase of inﬂammation, RvE1 accelerates the clear-
ance of airway inﬂammation, mucus metaplasia, and hyper-
reactivity to methacholine (Haworth et al., 2008, 2011). These
RvE1-mediated bronchoprotective actions during resolution are
multi-pronged, including inhibition of Th17 effector lympho-
cytes, engagement of activated NK cells and increased generation
of interferon-gamma (IFN-g) and LXA4 (Haworth et al., 2008,
2011). After cessation of allergen exposure, the timely resolu-
tion of allergic airway responses is governed by regulation of
the Th17 pathway (Haworth et al., 2008). This is in sharp con-
trast to the pivotal roles for Th2 cytokines during the devel-
opment of allergic lung inﬂammation (vide supra). IL-17 can
be generated by several cell types in asthmatic lung, including
Th17 cells that are a subset of CD4C T helper cells character-
ized by the production of IL-17 and whose population expansion
and survival depends upon IL-23. IL-17 has been linked to the
pathogenesis of many inﬂammatory diseases, is present in the
airways of asthmatic patients and can induce lung inﬂamma-
tion, airway hyper-reactivity and mucus production (Chen et al.,
2003; Haworth et al., 2008; Al-Ramli et al., 2009; Alcorn et al.,
2010; Lajoie et al., 2010). Similar to RvD1 and AT-RvD1, RvE1
also regulates IL-17 to promote resolution of allergic airways
responses.
Identiﬁcation of an important role for IL-17 in the persis-
tence of lung inﬂammation, in particular during allergic airway
inﬂammation, is supported by several lines of evidence. Trans-
genic expression of IL-17 in airway epithelial cells induces airway
eosinophil and lymphocyte inﬁltration and structural changes
with mucus metaplasia (Park et al., 2005). Mice deﬁcient for
the IL-17 receptor are protected from allergen-induced airway
inﬂammation (Schnyder-Candrian et al., 2006), and in humans,
asthmatic subjects have higher levels of BALF and sputum IL-
17 (Molet et al., 2001; Barczyk et al., 2003; Schnyder-Candrian
et al., 2006). Indicative of its importance in the lung, IL-17 may
have dual roles in the regulation of allergic airway inﬂammation,
as it can also inhibit TH2 immune responses in model systems
(Schnyder-Candrian et al., 2006). In promoting resolution, RvE1
signiﬁcantly decreases both IL-17 and allergic airway responses
(Haworth et al., 2008), supporting a relationship between IL-17
and persistent airway inﬂammation.
In addition to IL-17,BALF levels of IL-23 are also decreased by
administrationof RvE1.IL-23isalsoinvolvedinthepathobiology
of chronic inﬂammatory diseases, including colitis, encephalitis,
psoriasis, rheumatoid arthritis, and cancer (Langrish et al., 2005;
Chan et al., 2006; Langowski et al., 2006; Yago et al., 2007), and
IL-23iscriticalforthesurvivalof TH17cells(Langrishetal.,2005;
Bettellietal.,2006).IL-23inducesthereleaseof pro-inﬂammatory
chemokines from eosinophils, which express the IL-23 receptor
(Cheungetal.,2008).Moreover,IL-23deﬁcientmiceareprotected
inmodelsofchronicinﬂammation,suchascolitis(Yenetal.,2006).
Of note, RvE1 also protects against the development of colitis in
modelsystems(Aritaetal.,2005b;Hudertetal.,2006).Thus,regu-
lationof IL-23byRvE1appearscriticaltoitspro-resolvingactions
in mucosal inﬂammation.
As mentioned above, NK cells express the RvE1 receptor
CMKLR1 (Arita et al., 2005a; Parolini et al., 2007). NK cell deple-
tion impairs RvE1’s protective actions for the timely resolution
of adaptive inﬂammation (Haworth et al., 2011). RvE1 regulates
NK cell homing, increases clearance of antigen-speciﬁc CD4C
T cells and increases NK cell cytotoxicity. Circulating and lung
NK cell numbers increase with RvE1 administration, consistent
with a role for RvE1 in NK cell transit through the inﬂamed lung
to its associated mediastinal lymph nodes. RvE1 induces CXCL9
expression in the lung and mediastinal lymph nodes. Antibody-
mediatedinhibitionofCXCL9-CXCR3interactionsblocksNKcell
inﬁltration into inﬂamed lung and lymph nodes, and delays res-
olution of adaptive airway inﬂammation. These ﬁndings indicate
thatRvE1canregulatetissuechemokinestotargetNKcellhoming
to the lung for catabasis. The inﬂuence of D-series resolvins and
ALX/FPR2 signaling on NK cell functional responses is an area of
active investigation.
Current anti-inﬂammatory therapeutic strategies for asthma
include corticosteroids, CysLT1 receptor antagonists and anti-
IgE antibody (Fanta, 2009). While little is known regarding
the inﬂuence of these approaches on the actions of resolvins,
their independent signaling pathways suggest that the resolvins
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would complement existing therapeutics. Corticosteroids share
the resolvins’ anti-inﬂammatory actions on eosinophils and T
cells; however, they do not share resolvins’ pro-resolving actions
for macrophages and NK cells. CysLT1 receptor antagonists
and anti-IgE antibody target speciﬁc pro-phlogistic pathways
and would not be expected to interfere with the resolvins’
mechanisms of action. Regarding pharmacological considera-
tions for the resolvins, these mediators carry potent actions
in sub-nanomolar concentrations in vitro (reviewed in Serhan,
2007) and at doses of s0.005mg/kg in vivo (Haworth et al.,
2008; Rogerio et al., 2012). As with the Fat-1 transgenic mouse
(Bilal et al., 2011), increasing the tissue levels of omega-3 fatty
acids can increase resolvin formation and offer protection from
allergic airway responses; however, dietary supplementation is
less potent than direct administration of resolvins (Seki et al.,
2010).
SHARED AND DISTINCT PRO-RESOLVING MECHANISMS FOR
RvE1 AND RvD1/AT-RvD1 IN ADAPTIVE INFLAMMATION
RvE1 and RvD1/AT-RvD1 are agonists at distinct pro-resolving
receptors, yet share many similar properties in the regulation of
adaptive inﬂammation in the lung (Figure 1, Table 2). These
mediators decrease recruitment of lung eosinophils,lymphocytes,
andmacrophagesduringadaptiveimmuneresponsesanddecrease
allergic airway responses,including mucus metaplasia and hyper-
responsiveness to methacholine. In addition, these specialized
pro-resolving mediators share many similarities in the regula-
tion of lung inﬂammatory peptide and lipid mediators. Despite
these commonalities,the RvE1 and RvD1/AT-RvD1 pro-resolving
pathways are not entirely redundant. In addition to their distinct
Table 2 | Shared and distinct pro-resolving mechanisms for RvE1 and
RvD1/AT-RvD1 during murine adaptive inﬂammation.
Receptors RvE1 RvD1/AT-RvD1 LXA4 analog
CMKLR1 BLT1 ALX/FPR2 ALX/FPR2 CysLT1
ALLERGICAIRWAY RESPONSES
Inﬂammation
Eosinophils Decreased Decreased Decreased
Lymphocytes Decreased Decreased Decreased
NK Cells Increased
Macrophages Decreased Increased
Mucus metaplasia Decreased Decreased Decreased
MCh ED200 Increased Increased Increased
CYTOKINES
IL -4 No change No change
IL -5 No change Decreased
IL -6 Decreased
IL -10 No change No change
IL -13 No change No change
IL -17 Decreased Decreased Decreased
IL -23 Decreased Decreased No change
IL -27 Decreased
Interferon-gamma Increased No change Decreased
CHEMOKINES
Eotaxin Decreased
TARC Decreased
LIPID MEDIATORS
LTB4 Decreased Decreased
CysLTs No change
LXA4 Increased No change
FIGURE 1 | Cellular targets for resolvins in allergic inﬂammation.
Shared and distinct anti-phlogistic and pro-resolving actions are
illustrated for RvD1 (D1) and RvE1 (E1).These natural mediators have
independent signaling pathways initiated via interactions with distinct
receptors, yet they share many overlapping properties at the cellular
and tissue levels.
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receptors,there are clear differences between RvE1 and RvD1/AT-
RvD1 in the regulation of BALF levels of IL-5, IFN-g, and LXA4
duringresolution(Haworthetal.,2008,2011;Rogerioetal.,2012).
WhilethereisnodataonconcomitantadministrationofRvE1and
RvD1 in this model, co-administration of RvE1 and a bioactive
LXA4 stable analog, which, like RvD1/AT-RvD1, interacts with
ALX/FPR2 receptors, provides additive pro-resolving actions, yet
there are important differences in their mechanisms. Both RvE1
and the LXA4 analog decrease BALF levels of IL-17, but distinct
from RvE1, the LXA4 analog does not inhibit IL-23 production
or increase IFN-g levels (Haworth et al., 2008). These ﬁndings of
shared and distinct points of counter-regulation for RvE1 and
the LXA4 stable analog indicate the presence of independent
pro-resolving signaling circuits, likely mediated by CMKLR1 and
ALX/FPR2 respectively, which in this model of adaptive immu-
nity converge on the regulation of IL-17 to promote catabasis
(Table 2). Of interest, when administered during the upstroke
of allergic inﬂammation, both RvD1 and RvE1 are also potent
regulators of the development of airway hyper-responsiveness to
methacholine, mucus metaplasia, eosinophil accumulation, and
TH2 cytokine mediator release (e.g., IL-13; Haworth et al., 2008,
2011). Regulation of IL-13 by resolvins during induction of adap-
tiveinﬂammationisdistinctfromtheiractionswhengivenduring
resolution. When given after the adaptive inﬂammation is already
established, these resolvins do not lead to signiﬁcant changes in
BALF levels of IL-13; however, both RvD1 and RvE1 lead to
marked decreases in BALF levels of IL-17. While the mecha-
nisms that induce adaptive inﬂammation (i.e., TH2 cytokines)
are distinct from those linked to persistent mucosal inﬂamma-
tion (i.e., IL-17 and IL-23), the protective actions of resolvins
include regulation of both of these important families of inﬂam-
matory mediators. Inhibition of IL-17 production appears to be
a common point of regulation for RvE1 and RvD1 for resolution
of allergic airway responses (Serhan et al., 2000; Haworth et al.,
2011).
SUMMARY AND CONCLUSIONS
The recent discovery of resolvins, endogenously gener-
ated from the essential fatty acids docosahexaenoic acid
and eicosapentaenoic acid, has uncovered molecular and
cellular mechanisms for the resolution of acute and adaptive
inﬂammation. These specialized and stereospeciﬁc pro-resolving
chemical mediators play important roles in limiting allergic air-
wayresponsesandpromotingcatabasisoftheinﬂamedlung.Inthe
lung, resolvins are enzymatically generated during cell–cell inter-
actions,often between leukocytes and structural cells. Their inter-
actions with speciﬁc receptors establish resolution circuits with
celltypespeciﬁcfunctionalresponses.WhileRvD1andRvE1share
some cellular targets and pro-resolving actions, there is accumu-
latingevidencefordistinctcounter-regulatorysignalingpathways,
including distinct receptors. In response to acute inﬂammation,
these endogenous mediators blunt the inﬂammatory response by
inhibiting aberrant neutrophil trafﬁcking and activation, stimu-
lating efferocytosis of apoptotic neutrophils and promoting anti-
angiogenic, anti-ﬁbrotic, and anti-infective actions. In allergic
immune responses, resolvins enlist NK cells to facilitate clearance
of activated T cells and activate macrophages (in a non-phlogistic
manner)forphagocyticremovalof allergendepositedininﬂamed
lung. Rapidly formed during inﬂammatory responses,these auta-
coids are also rapidly inactivated by eicosanoid oxidoreductases.
In the setting of chronic inﬂammatory lung disease, airway levels
of omega-3 fatty acids and pro-resolving mediators are decreased.
With no curative therapy currently available for asthma or sev-
eral other chronic inﬂammatory diseases, the development of
resolvin stable analogs is leading to exciting new potential ther-
apeutic approaches in acute and adaptive chronic inﬂammation
that emphasize these natural homeostatic pathways.
ACKNOWLEDGMENTS
This work was supported in part by US National Institutes of
Health grants AI068084, HL068669, and GM095467.
REFERENCES
Alcorn, J. F., Crowe, C. R., and Kolls,
J. K. (2010). TH17 cells in asthma,
and COPD. Annu. Rev. Physiol. 72,
495–516.
Al-Ramli,W., Prefontaine, D., Chouiali,
F., Martin, J. G., Olivenstein,
R., Lemière, C., et al. (2009).
TH17-associated cytokines IL-17A
and IL-17F in severe asthma.
J. Allergy Clin. Immunol. 123,
1185–1187.
Aoki,H.,Hisada,T.,Ishizuka,T.,Utsugi,
M., Kawata, T., Shimizu, Y., et al.
(2008).ResolvinE1dampensairway
inﬂammation,andhyperresponsive-
ness in a murine model of asthma.
Biochem. Biophys. Res. Commun.
367, 509–515.
Ariel, A., Chiang, N., Arita, M., Peta-
sis, N. A., and Serhan, C. N.
(2003).Aspirin-triggeredlipoxinA4,
and B4 analogs block extracellular
signal-regulated kinase-dependent
TNF-alpha secretion from human T
cells. J. Immunol. 170, 6266–6272.
Arita, M., Bianchini, F., Aliberti, J.,
Sher, A., Chiang, N., Hong, S., et al.
(2005a).Stereochemicalassignment,
antiinﬂammatory properties, and
receptorfortheomega-3lipidmedi-
ator resolvin E1. J. Exp. Med. 201,
713–722.
Arita, M., Yoshida, M., Hong, S.,
Tjonahen, E., Glickman, J. N.,
Petasis, N. A., et al. (2005b).
Resolvin E1, an endogenous lipid
mediator derived from omega-3
eicosapentaenoic acid, protects
against 2,4,6-trinitrobenzene
sulfonic acid-induced colitis.
Proc. Natl. Acad. Sci. U.S.A. 102,
7671–7676.
Arita, M., Ohira, T., Sun, Y. P., Elan-
govan, S., Chiang, N., and Ser-
han, C. N. (2007). Resolvin E1
selectively interacts with leukotriene
B4 receptor BLT1, and ChemR23 to
regulate inﬂammation. J. Immunol.
178, 3912–3917.
Barczyk, A., Pierzchala, W., and Sozan-
ska,E.(2003).Interleukin-17inspu-
tum correlates with airway hyper-
responsiveness to methacholine.
Respir. Med. 97, 726–733.
Bettelli, E., Carrier, Y., Gao, W., Korn,
T., Strom, T. B., Oukka, M., et
al.(2006).Reciprocaldevelopmental
pathwaysforthegenerationof path-
ogeniceffectorTH17,andregulatory
T cells. Nature 441, 235–238.
Bhavsar, P. K., Levy, B. D., Hew, M. J.,
Pfeffer, M. A., Kazani, S., Israel, E.,
etal.(2010).Corticosteroidsuppres-
sion of lipoxin A4, and leukotriene
B4 from alveolar macrophages in
severe asthma. Respir. Res. 11, 71.
Bilal, S., Haworth, O., Wu, L.,
Weylandt, K. H., Levy, B. D.,
and Kang, J. X. (2011). Fat-1
transgenic mice with elevated
omega-3 fatty acids are protected
from allergic airway responses.
Biochim. Biophys. Acta 1812,
1164–1169.
Bondue, B., Vosters, O., de Nadai, P.,
Glineur, S., De Henau, O., Luangsay,
S., et al. (2011). ChemR23 dampens
lung inﬂammation, and enhances
anti-viral immunity in a mouse
model of acute viral pneumonia.
PLoS Pathog. 7:e1002358.
doi:10.1371/journal.ppat.
1002358
Bonnans, C., Fukunaga, K., Levy,
M. A., and Levy, B. D. (2006).
Lipoxin A4 regulates bronchial
epithelial cell responses to
acid injury. Am. J. Pathol. 168,
1064–1072.
Bonnans, C., Mainprice, B., Chanez, P.,
Bousquet, J., and Urbach,V. (2003).
Lipoxin A4 stimulates a cytosolic
Ca2 increase in human bronchial
epithelium. J. Biol. Chem. 278,
10879–10884.
www.frontiersin.org December 2012 | Volume 3 | Article 390 | 7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Levy Resolvins in allergic airway inﬂammation
Bozinovski,S.,Hutchinson,A.,Thomp-
son, M., Macgregor, L., Black, J.,
Giannakis, E., et al. (2008). Serum
amyloid a is a biomarker of acute
exacerbationsof chronicobstructive
pulmonary disease. Am. J. Respir.
Crit. Care Med. 177, 269–278.
Bozinovski, S., Uddin, M., Vlahos, R.,
Thompson, M., McQualter, J. L.,
Merritt, A. S., et al. (2012). Serum
amyloid A opposes lipoxin A4 to
mediate glucocorticoid refractory
lung inﬂammation in chronic
obstructive pulmonary disease.
Proc. Natl. Acad. Sci. U.S.A. 109,
935–940.
Busse, W. W., and Lemanske, R. F. Jr.
(2001).Asthma.N.Engl.J.Med.344,
350–362.
Cash, J. L., Hart, R., Russ, A., Dixon,
J. P., Colledge, W. H., Doran, J.,
et al. (2008). Synthetic chemerin-
derived peptides suppress inﬂam-
mation through ChemR23. J. Exp.
Med. 205, 767–775.
Celik,G. E.,Erkekol,F. O.,Misirligil,Z.,
andMelli,M.(2007).LipoxinA4lev-
els in asthma: relation with disease
severity,and aspirinsensitivity.Clin.
Exp. Allergy 37, 1494–1501.
Chan, J. R., Blumenschein, W., Mur-
phy, E., Diveu, C., Wiekowski, M.,
Abbondanzo, S., et al. (2006). IL-23
stimulatesepidermalhyperplasiavia
TNF,andIL-20R2-dependentmech-
anisms with implications for psori-
asis pathogenesis. J. Exp. Med. 203,
2577–2587.
Chen, Y., Thai, P., Zhao, Y. H.,
Ho, Y. S., DeSouza, M. M., and
Wu, R. (2003). Stimulation of air-
way mucin gene expression by
interleukin IL-17 through IL-6
paracrine/autocrine loop. J. Biol.
Chem. 278, 17036–17043.
Cheung, P. F., Wong, C. K., and Lam,
C. W. (2008). Molecular Mecha-
nisms of cytokine, and chemokine
release from eosinophils activated
by IL-17A, IL-17F, and IL-23:
implication for Th17 lymphocytes-
mediated allergic inﬂammation. J.
Immunol. 180, 5625–5635.
Chiang,N.,Serhan,C. N.,Dahlen,S. E.,
Drazen, J. M., Hay, D. W., Rovati, G.
E., et al. (2006). The lipoxin recep-
tor ALX: potent ligand-speciﬁc, and
stereoselective actions in vivo. Phar-
macol. Rev. 58, 463–487.
Chiron, R., Grumbach, Y. Y., Quynh,
N. V., Verriere, V., and Urbach, V.
(2008). LipoxinA4,andinterleukin-
8 levels in cystic ﬁbrosis sputum
after antibiotherapy. J. Cyst. Fibros.
7, 463–468.
Christie, P. E., Spur, B. W., and Lee,
T. H. (1992). The effects of lipoxin
A4 on airway responses in asthmatic
subjects. Am. Rev. Respir. Dis. 145,
1281–1284.
Corry, D. B., and Irvin, C. G. (2006).
Promise, and pitfalls in animal-
based asthma research: building a
better mousetrap. Immunol. Res. 35,
279–294.
Demoor, T., Bracke, K. R., Dupont,
L. L., Plantinga, M., Bondue, B.,
Roy, M. O., et al. (2011). The
role of ChemR23 in the induction,
and resolution of cigarette smoke-
induced inﬂammation. J. Immunol.
186, 5457–5467.
Devchand, P. R., Arita, M., Hong, S.,
Bannenberg, G., Moussignac, R. L.,
Gronert, K., et al. (2003). Human
ALX receptor regulates neutrophil
recruitmentintransgenicmice:roles
in inﬂammation, and host defense.
FASEB J. 17, 652–659.
Dufton, N., Hannon, R., Brancaleone,
V., Dalli, J., Patel, H. B., Gray,
M.,et al. (2010).Anti-inﬂammatory
role of the murine formyl-peptide
receptor 2: ligand-speciﬁc effects
on leukocyte responses, and exper-
imental inﬂammation. J. Immunol.
184, 2611–2619.
Eickmeier, O., Seki, H., Haworth, O.,
Hilberath,J.N.,Gao,F.,Uddin,M.,et
al.(2012).Aspirin-triggeredresolvin
D1 reduces mucosal inﬂammation,
andpromotesresolutioninamurine
model of acute lung injury. Mucosal
Immunol. doi:10.1038/mi.2012.66
El Kebir, D., Gjorstrup, P., and Filep,
J. G. (2012). Resolvin E1 pro-
motes phagocytosis-induced neu-
trophil apoptosis, and accelerates
resolution of pulmonary inﬂamma-
tion.Proc.Natl.Acad.Sci.U.S.A.109,
14983–14988.
Fanta, C. H. (2009). Asthma. N. Engl. J.
Med. 360, 1002–1014.
Fiore, S., Maddox, J. F., Perez, H. D.,
and Serhan, C. N. (1994). Identiﬁ-
cation of a human cDNA encoding
a functional high afﬁnity lipoxin A4
receptor. J. Exp. Med. 180, 253–260.
Fiore, S., Ryeom, S. W., Weller, P. F.,
and Serhan, C. N. (1992). Lipoxin
recognition sites. Speciﬁc binding
of labeled lipoxin A4 with human
neutrophils. J. Biol. Chem. 267,
16168–16176.
Freedman, S. D., Blanco, P. G., Zaman,
M. M., Shea, J. C., Ollero, M., Hop-
per, I. K., et al. (2004). Association
of cystic ﬁbrosis with abnormalities
in fatty acid metabolism. N. Engl. J.
Med. 350, 560–569.
Fritscher, L. G., Post, M., Rodrigues, M.
T., Silverman, F., Balter, M., Chap-
man, K. R., et al. (2012). Proﬁle of
eicosanoids in breath condensate in
asthma, and COPD. J. Breath Res. 6,
1–5.
Godson, C., Mitchell, S., Harvey, K.,
Petasis, N. A., Hogg, N., and
Brady, H. R. (2000). Cutting edge:
lipoxins rapidly stimulate non-
phlogistic phagocytosis of apop-
totic neutrophils by monocyte-
derived macrophages. J. Immunol.
164, 1663–1667.
Gronert, K., Gewirtz, A., Madara, J. L.,
andSerhan,C.N.(1998).Identiﬁca-
tion of a human enterocyte lipoxin
A4receptorthatisregulatedbyinter-
leukinIL-13,andinterferongamma,
and inhibits tumor necrosis factor
alpha-induced IL-8 release. J. Exp.
Med. 187, 1285–1294.
Hasan, R. A., O’Brien, E., and Man-
cuso, P. (2012). Lipoxin A4, and 8-
isoprostane in the exhaled breath
condensate of children hospitalized
for status asthmaticus. Pediatr. Crit.
Care Med. 13, 141–145.
Haworth, O., Cernadas, M., and Levy,
B. D. (2011). NK cells are effectors
for resolvin E1 in the timely resolu-
tionofallergicairwayinﬂammation.
J. Immunol. 186, 6129–6135.
Haworth, O., Cernadas, M., Yang, R.,
Serhan,C.N.,andLevy,B.D.(2008).
Resolvin E1 regulates interleukin 23,
interferon-gamma, and lipoxin A4
to promote the resolution of allergic
airwayinﬂammation.Nat.Immunol.
9, 873–879.
Hudert, C. A., Weylandt, K. H., Lu, Y.,
Wang, J., Hong, S., Dignass, A., et
al. (2006). Transgenic mice rich in
endogenous omega-3 fatty acids are
protected from colitis. Proc. Natl.
Acad. Sci. U.S.A. 103, 11276–11281.
Isobe, Y., Arita, M., Matsueda, S.,
Iwamoto,R.,Fujihara,T.,Nakanishi,
H., et al. (2012). Identiﬁcation,
and structure determination
of novel anti-inﬂammatory
mediator resolvin E3, 17,18-
dihydroxyeicosapentaenoic acid. J.
Biol. Chem. 287, 10525–10534.
Karp, C. L., Flick, L. M., Park, K. W.,
Softic, S., Greer, T. M., Keledjian,
R., et al. (2004). Defective lipoxin-
mediated anti-inﬂammatory activ-
ity in the cystic ﬁbrosis airway. Nat.
Immunol. 5, 388–392.
Kips, J. C., Anderson, G. P., Fredberg, J.
J., Herz, U., Inman, M. D., Jordana,
M., et al. (2003). Murine models of
asthma. Eur. Respir. J. 22, 374–382.
Kowal-Bielecka, O., Kowal, K., Distler,
O.,Rojewska,J.,Bodzenta-Lukaszyk,
A., Michel, B. A., et al. (2005).
Cyclooxygenase-, and lipoxygenase-
derived eicosanoids in bronchoalve-
olar lavage ﬂuid from patients with
scleroderma lung disease: an imbal-
ance between proinﬂammatory, and
antiinﬂammatory lipid mediators.
Arthritis Rheum. 52, 3783–3791.
Krishnamoorthy, S., Recchiuti, A., Chi-
ang, N., Fredman, G., and Ser-
han, C. N. (2012). Resolvin D1
receptor stereoselectivity, and regu-
lation of inﬂammation, and prore-
solving microRNAs. Am. J. Pathol.
180, 2018–2027.
Krishnamoorthy, S., Recchiuti, A., Chi-
ang, N., Yacoubian, S., Lee, C. H.,
Yang, R., et al. (2010). Resolvin
D1 binds human phagocytes with
evidence for proresolving receptors.
Proc. Natl. Acad. Sci. U.S.A. 107,
1660–1665.
Lajoie, S., Lewkowich, I. P., Suzuki, Y.,
Clark, J. R., Sproles, A. A., Dienger,
K., et al. (2010). Complement-
mediated regulation of the IL-17A
axis is a central genetic determi-
nant of the severity of experimental
allergic asthma. Nat. Immunol. 11,
928–935.
Langowski,J.L.,Zhang,X.,Wu,L.,Matt-
son, J. D., Chen, T., Smith, K., et
al. (2006). IL-23 promotes tumour
incidence, and growth. Nature 442,
461–465.
Langrish,C.L.,Chen,Y.,Blumenschein,
W.M.,Mattson,J.,Basham,B.,Sedg-
wick,J. D.,et al. (2005). IL-23 drives
a pathogenic T cell population that
inducesautoimmuneinﬂammation.
J. Exp. Med. 201, 233–240.
Levy, B. D. (2010).“Asthma,” in Funda-
mentals of Inﬂammation, eds C. N.
Serhan,P.A.Ward,andD.W.Gilroy,
1st Edn (NewYork: Cambridge Uni-
versity Press), 376–84.
Levy, B. D., Bonnans, C., Silverman, E.
S., Palmer, L. J., Marigowda, G., and
Israel,E.(2005).Diminishedlipoxin
biosynthesisinsevereasthma.Am.J.
Respir.Crit.CareMed.172,824–830.
Levy, B. D., De Sanctis, G. T., Devc-
hand, P. R., Kim, E., Ackerman,
K., Schmidt, B. A., et al. (2002).
Multi-pronged inhibition of airway
hyper-responsiveness, and inﬂam-
mation by lipoxin A4. Nat. Med. 8,
1018–1023.
Levy, B. D., Kohli, P., Gotlinger, K.,
Haworth, O., Hong, S., Kazani, S.,
et al. (2007). Protectin D1 is gener-
ated in asthma,and dampens airway
inﬂammation,andhyperresponsive-
ness. J. Immunol. 178, 496–502.
Luangsay, S., Wittamer, V., Bondue,
B., De Henau, O., Rouger, L.,
Brait, M., et al. (2009). Mouse
ChemR23 is expressed in den-
dritic cell subsets,and macrophages,
and mediates an anti-inﬂammatory
activity of chemerin in a lung
disease model. J. Immunol. 183,
6489–6499.
Maddox,J. F.,and Serhan,C. N. (1996).
Lipoxin A4, and B4 are potent stim-
uli for human monocyte migration,
Frontiers in Immunology | Inﬂammation December 2012 | Volume 3 | Article 390 | 8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Levy Resolvins in allergic airway inﬂammation
and adhesion: selective inactivation
by dehydrogenation, and reduction.
J. Exp. Med. 183, 137–146.
Majno,G.(1996).Cells,Tissues,andDis-
ease: Principles of General Pathology.
Cambridge, MA: Blackwell.
Mattoscio,D.,Evangelista,V.,DeCristo-
faro, R., Recchiuti, A., Pandolﬁ,
A., Di Silvestre, S., et al. (2010).
Cystic ﬁbrosis transmembrane con-
ductance regulator CFTR expres-
sion in human platelets: impact on
mediators, and mechanisms of the
inﬂammatoryresponse.FASEBJ.24,
3970–3980.
Molet, S., Hamid, Q., Davoine, F.,
Nutku, E., Taha, R., Pagé, N., et al.
(2001). IL-17 is increased in asth-
matic airways, and induces human
bronchial ﬁbroblasts to produce
cytokines. J. Allergy Clin. Immunol.
108, 430–438.
Monnier, J., Lewén, S., O’Hara, E.,
Huang, K., Tu, H., Butcher, E. C.,
et al. (2012). Expression, regulation,
and function of atypical chemerin
receptorCCRL2onendothelialcells.
J. Immunol. 189, 956–967.
Morris,T.,Stables,M.,Colville-Nash,P.,
Newson,J.,Bellingan,G.,deSouza,P.
M.,etal.(2010).Dichotomyindura-
tion, and severity of acute inﬂam-
matory responses in humans arising
from differentiallyexpressedprores-
olution pathways. Proc. Natl. Acad.
Sci. U.S.A. 107, 8842–8847.
Norling,L.V.,Dalli,J.,Flower,R. J.,Ser-
han, C. N., and Perretti, M. (2012).
Resolvin D1 limits PMN recruit-
ment to inﬂammatory loci: recep-
tor dependent actions. Arterioscler.
Thromb. Vasc. Biol. 32, 1970–1978.
Oh,S.F.,Dona,M.,Fredman,G.,Krish-
namoorthy, S., Irimia, D., and Ser-
han, C. N. (2012). Resolvin E2 for-
mation, and impact in inﬂamma-
tion resolution. J. Immunol. 188,
4527–4534.
Park, H., Li, Z., Yang, X. O., Chang, S.
H., Nurieva, R., Wang, Y. H., et al.
(2005). A distinct lineage of CD4 T
cells regulates tissue inﬂammation
by producing interleukin 17. Nat.
Immunol. 6, 1133–1141.
Parolini, S., Santoro, A., Marcenaro, E.,
Luini, W., Massardi, L., Facchetti, F.,
et al. (2007). The role of chemerin
in the colocalization of, N. K., and
dendritic cell subsets into inﬂamed
tissues. Blood 109, 3625–3632.
Perretti, M., Chiang, N., La, M., Fierro,
I. M., Marullo, S., Getting, S. J., et
al. (2002). Endogenous lipid-, and
peptide-derived anti-inﬂammatory
pathways generated withglucocorti-
coid, and aspirin treatment activate
the lipoxin A4 receptor. Nat. Med. 8,
1296–1302.
Pichavant, M., Goya, S., Hamelmann,
E., Gelfand, E. W., and Umetsu, D.
T. (2007). Animal models of airway
sensitization.Curr.Protoc.Immunol.
Chapter 15, Unit 15 8.
Planaguma, A., Kazani, S., Marigowda,
G.,Haworth,O.,Mariani,T.J.,Israel,
E., et al. (2008). Airway lipoxin A4
generation, and lipoxin A4 receptor
expression are decreased in severe
asthma.Am.J.Respir.Crit.CareMed.
178, 574–582.
Ramstedt, U., Serhan, C. N., Nicolaou,
K. C.,Webber,S. E.,Wigzell,H.,and
Samuelsson, B. (1987). Lipoxin A-
induced inhibition of human nat-
ural killer cell cytotoxicity: stud-
ies on stereospeciﬁcity of inhibition,
andmodeofaction.J.Immunol.138,
266–270.
Rogerio, A. P., Haworth, O., Croze,
R., Oh, S. F., Uddin, M., Carlo,
T., et al. (2012). Resolvin d1, and
aspirin-triggered resolvin d1 pro-
mote resolution of allergic air-
ways responses. J. Immunol. 189,
1983–1991.
Sanak,M.,Levy,B. D.,Clish,C. B.,Chi-
ang, N., Gronert, K., Mastalerz, L.,
et al. (2000). Aspirin-tolerant asth-
matics generate more lipoxins than
aspirin-intolerant asthmatics. Eur.
Respir. J. 16, 44–49.
Schnyder-Candrian, S., Togbe, D.,
Couillin, I., Mercier, I., Brombacher,
F., Quesniaux, V., et al. (2006).
Interleukin-17 is a negative regula-
tor of established allergic asthma. J.
Exp. Med. 203, 2715–2725.
Schwab, J. M., Chiang, N., Arita,
M., and Serhan, C. N. (2007).
Resolvin E1, and protectin D1 acti-
vate inﬂammation-resolution pro-
grammes. Nature 447, 869–874.
Seki, H., Fukunaga, K., Arita, M., Arai,
H., Nakanishi, H., Taguchi, R., et
al. (2010). The anti-inﬂammatory,
and proresolving mediator resolvin
E1 protects mice from bac-
terial pneumonia, and acute
lung injury. J. Immunol. 184,
836–843.
Serhan, C. N. (2007). Resolution phase
of inﬂammation: novel endogenous
anti-inﬂammatory, and proresolv-
ing lipid mediators, and pathways.
Annu. Rev. Immunol. 25, 101–137.
Serhan,C.N.,Chiang,N.,andVanDyke,
T. E. (2008). Resolving inﬂamma-
tion: dual anti-inﬂammatory, and
pro-resolution lipid mediators. Nat.
Rev. Immunol. 8, 349–361.
Serhan, C. N., Clish, C. B., Brannon,
J., Colgan, S. P., Chiang, N., and
Gronert, K. (2000). Novel func-
tionalsetsoflipid-derivedmediators
with antiinﬂammatory actions gen-
erated from omega-3 fatty acids via
cyclooxygenase 2-nonsteroidal anti-
inﬂammatory drugs, and transcel-
lular processing. J. Exp. Med. 192,
1197–1204.
Serhan, C. N., Hong, S., Gronert, K.,
Colgan, S. P., Devchand, P. R., Mir-
ick, G., et al. (2002). Resolvins:
a family of bioactive products of
omega-3 fatty acid transformation
circuits initiated by aspirin treat-
ment that counter proinﬂammation
signals.J.Exp.Med.196,1025–1037.
Simiele, F., Recchiuti, A., Mattoscio, D.,
De Luca, A., Cianci, E., Franchi, S.,
et al. (2011). Transcriptional regula-
tion of the human FPR2/ALX gene:
evidence of a heritable genetic vari-
ant that impairs promoter activity.
FASEB J. 26, 1323–1333.
Sodin-Semrl, S., Taddeo, B., Tseng,
D., Varga, J., and Fiore, S. (2000).
Lipoxin A4 inhibits IL-1 beta-
induced IL-6, IL-8, and matrix
metalloproteinase-3 production
in human synovial ﬁbroblasts,
and enhances synthesis of tissue
inhibitors of metalloproteinases. J.
Immunol. 164, 2660–2666.
Stenke, L., Edenius, C., Samuelsson, J.,
and Lindgren,J.A. (1991). Deﬁcient
lipoxin synthesis: a novel platelet
dysfunction in myeloproliferative
disorders with special reference to
blasticcrisisofchronicmyelogenous
leukemia. Blood 78, 2989–2995.
Sun, Y. P., Oh, S. F., Uddin, J., Yang,
R., Gotlinger, K., Campbell, E., et al.
(2007). Resolvin D1,and its aspirin-
triggered 17R epimer. Stereochemi-
cal assignments, anti-inﬂammatory
properties, and enzymatic inactiva-
tion. J. Biol. Chem. 282, 9323–9334.
Tahan, F., Saraymen, R., and Gumus,
H. (2008). The role of lipoxin
A4inexercise-inducedbronchocon-
striction in asthma. J. Asthma 45,
161–164.
Terawaki, K., Yokomizo, T., Nagase, T.,
Toda,A.,Taniguchi,M.,Hashizume,
K., et al. (2005). Absence of
leukotriene B4 receptor 1 confers
resistance to airway hyperre-
sponsiveness, and Th2-type
immune responses. J. Immunol.
175, 4217–4225.
Thornton, E. E., Looney, M. R., Bose,
O., Sen, D., Sheppard, D., Locksley,
R., et al. (2012). Spatiotemporally
separated antigen uptake by alveolar
dendritic cells, and airway presenta-
tion to T cells in the lung. J. Exp.
Med. 209, 1183–1199.
Tjonahen, E., Oh, S. F., Siegel-
man, J., Elangovan, S., Percarpio,
K. B., Hong, S., et al. (2006).
ResolvinE2:identiﬁcation,andanti-
inﬂammatoryactions:pivotalroleof
human 5-lipoxygenase in resolvin E
series biosynthesis. Chem. Biol. 13,
1193–1202.
Vachier, I., Bonnans, C., Chavis, C.,
Farce, M., Godard, P., Bousquet, J.,
et al. (2005). Severe asthma is asso-
ciatedwithalossof LX4,anendoge-
nousanti-inﬂammatorycompound.
J.Allergy Clin. Immunol. 115,55–60.
Wang, B., Gong, X., Wan, J. Y., Zhang,
L., Zhang, Z., Li, H. Z., et al. (2011).
ResolvinD1protectsmicefromLPS-
induced acute lung injury. Pulm.
Pharmacol. Ther. 24, 434–441.
Wong, D. T., Elovic, A., Matossian, K.,
Nagura, N., McBride, J., Chou, M.
Y., et al. (1991). Eosinophils from
patients with blood eosinophilia
express transforming growth factor
beta 1. Blood 78, 2702–2707.
Woodruff, P. G., Boushey, H. A.,
Dolganov, G. M., Barker, C. S.,
Yang, Y. H., Donnelly, S., et
al. (2007). Genome-wide proﬁling
identiﬁes epithelial cell genes asso-
ciated with asthma, and with treat-
ment response to corticosteroids.
Proc. Natl. Acad. Sci. U.S.A. 104,
15858–15863.
Wu, S. H., Yin, P. L., Zhang, Y. M., and
Tao, H. X. (2010). Reversed changes
of lipoxin A4, and leukotrienes in
children with asthma in different
severity degree. Pediatr. Pulmonol.
45, 333–340.
Yago, T., Nanke, Y., Kawamoto, M.,
Furuya, T., Kobashigawa, T.,
Kamatani, N., et al. (2007). IL-23
induces human osteoclastogenesis
via IL-17 in vitro, and anti-IL-23
antibody attenuates collagen-
induced arthritis in rats. Arthritis
Res. Ther. 9, R96.
Yamaguchi, H., Higashi, N., Mita, H.,
Ono, E., Komase, Y., Nakagawa, T.,
et al. (2011). Urinary concentra-
tions of 15-epimer of lipoxin A4
are lower in patients with aspirin-
intolerant compared with aspirin-
tolerant asthma. Clin. Exp. Allergy
41, 1711–1718.
Yang, J., Eiserich, J. P., Cross, C. E.,
Morrissey, B. M., and Hammock,
B. D. (2012). Metabolomic proﬁl-
ing of regulatory lipid mediators in
sputum from adult cystic ﬁbrosis
patients. Free Radic. Biol. Med. 53,
160–171.
Yang,L.,Cohn,L.,Zhang,D.H.,Homer,
R.,Ray,A.,andRay,P.(1998).Essen-
tial role of nuclear factor kappaB
in the induction of eosinophilia in
allergic airway inﬂammation. J. Exp.
Med. 188, 1739–1750.
Yen, D., Cheung, J., Scheerens, H.,
Poulet, F., McClanahan, T., McKen-
zie, B., et al. (2006). IL-23 is
essential for T cell-mediated colitis,
and promotes inﬂammation via
www.frontiersin.org December 2012 | Volume 3 | Article 390 | 9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Levy Resolvins in allergic airway inﬂammation
IL-17, and IL-6. J. Clin. Invest. 116,
1310–1316.
Zosky, G. R., and Sly, P. D. (2007). Ani-
mal models of asthma. Clin. Exp.
Allergy 37, 973–988.
Conﬂict of Interest Statement: Medi-
ators (resolvins and protectins) used
and evaluated in this study have been
licensed by the Brigham and Women’s
Hospital (BWH) to Resolvyx. Bruce D.
Levy has an equity interest in Resolvyx
and receives a share of licensing income
through BWH.
Received: 07 September 2012; accepted:
04 December 2012; published online: 28
December 2012.
Citation: Levy BD (2012) Resolvin D1
and resolvin E1 promote the resolu-
tion of allergic airway inﬂammation via
shared and distinct molecular counter-
regulatory pathways. Front. Immun.
3:390. doi: 10.3389/ﬁmmu.2012.00390
This article was submitted to Frontiers in
Inﬂammation, a specialty of Frontiers in
Immunology.
Copyright © 2012 Levy. This is an open-
access article distributed under the terms
of the Creative Commons Attribution
License, which permits use, distribution
and reproduction in other forums, pro-
vided the original authors and source
are credited and subject to any copy-
right notices concerning any third-party
graphics etc.
Frontiers in Immunology | Inﬂammation December 2012 | Volume 3 | Article 390 | 10